
|Videos|December 11, 2020
Implications of Expanding Use of CAR T-Cell Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)
A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.
Advertisement
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CGTlive®
1
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
2
Crawford Strunk, MD, on Integrating Gene Therapy into Clinical Care for Sickle Cell Disease
3
Janna Minehart, MD, on Hematology-Oncology Immunotherapy Highlights at ASH 2025
4
Integrating Gene Therapy into Clinical Care for Sickle Cell Disease
5

















































